Efficacy and safety of Amrith Noni Arthoplus in osteoarthritis: a double-blinded, randomized clinical trial
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20252574Keywords:
Bone mineral density, Morinda citrifolia, Noni, Osteoarthritis, Pain managementAbstract
Background: Osteoarthritis (OA) is a chronic, degenerative joint disorder marked by pain, inflammation, and impaired mobility, significantly affecting quality of life. Current treatments often provide limited relief and may have adverse effects with long-term use. This study aimed to evaluate the efficacy and safety of Amrith Noni Arthoplus in individuals with OA through a double-blinded, randomized clinical trial.
Methods: This double-blind, randomized, placebo-controlled study evaluated the efficacy and safety of Amrith Noni Arthoplus, an herbal formulation containing Morinda citrifolia (Noni) as the primary ingredient, in 40 patients with osteoarthritis (OA). Efficacy was evaluated using the visual analog scale (VAS) for pain intensity, 6-minute walk test, stair climb test, physician and subject global assessments (PGA/SGA), serum biomarkers (hs-CRP, calcium, phosphorus, magnesium, vitamin D3), and bone mineral density (BMD) via DEXA scans. Safety was assessed through vital signs, haematology, liver and kidney function tests, and adverse event monitoring.
Results: The active group demonstrated significant improvements in pain intensity (33.82% reduction in VAS scores, p<0.0001), physical function (14.17% increase in walking distance, p<0.0001), and stair climb time (12.75% reduction, p<0.0001) compared to the placebo group. Serum biomarkers, including hs-CRP (31.33% reduction, p<0.0001) and bone health markers (calcium, phosphorus, magnesium, vitamin D3), showed significant improvements. BMD increased by 25.48% in the active group (p<0.0001), while the placebo group experienced an 18.10% decline (p=0.002). No adverse events were reported, and all safety parameters remained within normal limits.
Conclusions: Amrith Noni Arthoplus significantly alleviates OA symptoms, improves physical function, and enhances bone health, demonstrating its potential as a safe and effective complementary therapy for OA management.
Metrics
References
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-59. DOI: https://doi.org/10.1016/S0140-6736(19)30417-9
Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. Lancet. 2015;386(9991):376-87. DOI: https://doi.org/10.1016/S0140-6736(14)60802-3
Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30. DOI: https://doi.org/10.1136/annrheumdis-2013-204763
Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115-26. DOI: https://doi.org/10.1016/S0140-6736(11)60243-2
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. DOI: https://doi.org/10.1016/j.joca.2014.01.003
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21-e33. DOI: https://doi.org/10.1016/S0140-6736(17)31744-0
Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. DOI: https://doi.org/10.1016/j.bcp.2020.114147
Osani MC, Lohmander LS, Bannuru RR. Is There Any Role for Opioids in the Management of Knee and Hip Osteoarthritis? A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2021;73(10):1413-24. DOI: https://doi.org/10.1002/acr.24363
Wang MY, West BJ, Jensen CJ, Nowicki D, Su C, Palu AK, et al. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacol Sin. 2002;23(12):1127-41.
Palu AK, Kim AH, West BJ, Deng S, Jensen J, White L. The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. J Ethnopharmacol. 2008;115(3):502-6. DOI: https://doi.org/10.1016/j.jep.2007.10.023
Pawlus AD, Kinghorn DA. Review of the ethnobotany, chemistry, biological activity and safety of the botanical dietary supplement Morinda citrifolia (noni). J Pharm Pharmacol. 2007;59(12):1587-609. DOI: https://doi.org/10.1211/jpp.59.12.0001
Su BN, Pawlus AD, Jung HA, Keller WJ, McLaughlin JL, Kinghorn AD. Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity. J Nat Prod. 2005;68(4):592-5. DOI: https://doi.org/10.1021/np0495985
Younos C, Rolland A, Fleurentin J, Lanhers MC, Misslin R, Mortier F. Analgesic and behavioural effects of Morinda citrifolia. Planta Med. 1990;56(5):430-4. DOI: https://doi.org/10.1055/s-2006-961004
Pearle AD, Scanzello CR, George S, Mandl LA, DiCarlo EF, Peterson M, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(5):516-23. DOI: https://doi.org/10.1016/j.joca.2006.10.010
Heaney RP. Bone health. Am J Clin Nutr. 2007;85(1):300S-303S. DOI: https://doi.org/10.1093/ajcn/85.1.300S
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-81. DOI: https://doi.org/10.1056/NEJMra070553
Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012;8(11):665-73. DOI: https://doi.org/10.1038/nrrheum.2012.130
Hussain S, Tamizhselvi R, George L, Manickam V. Assessment of the Role of Noni (Morinda citrifolia) Juice for Inducing Osteoblast Differentiation in Isolated Rat Bone Marrow Derived Mesenchymal Stem Cells. Int J Stem Cells. 2016;9(2):221-9. DOI: https://doi.org/10.15283/ijsc16024
Downloads
Published
How to Cite
Issue
Section
